MedTrace Logo

Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants

NCT04477837 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2024-08-21

No results posted yet for this study

Summary

Prospective comparison of the incidence of heavy menstrual bleeding (HMB) in women of reproductive age treated with direct oral anticoagulants (DOACs)

Conditions

  • Heavy Menstrual Bleeding

Interventions

DRUG

Apixaban 5 MG

frequency of heavy menstrual bleeding

DRUG

Rivaroxaban 20 MG

frequency of heavy menstrual bleeding

DRUG

Edoxaban 60 MG

frequency of heavy menstrual bleeding

DRUG

Dabigatran 150 Mg Oral Capsule

frequency of heavy menstrual bleeding

Sponsors & Collaborators

  • Cardioangiologisches Centrum Bethanien

    lead OTHER

Principal Investigators

  • Edelgard Lindhoff-Last, Prof. · Cardioangiologisches Zentrum Bethanien

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2024-05-31
Completion
2024-06-15

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04477837 on ClinicalTrials.gov